Equities research analysts expect that VBI Vaccines, Inc. – (NASDAQ:VBIV) will report earnings per share of ($0.25) for the current fiscal quarter, according to Zacks. Zero analysts have issued estimates for VBI Vaccines’ earnings. The business is scheduled to issue its next quarterly earnings report on Monday, January 1st.
On average, analysts expect that VBI Vaccines will report full-year earnings of ($0.90) per share for the current fiscal year, with EPS estimates ranging from ($0.92) to ($0.88). For the next financial year, analysts anticipate that the firm will post earnings of ($0.58) per share. Zacks Investment Research’s earnings per share averages are an average based on a survey of research firms that follow VBI Vaccines.
VBIV has been the subject of several recent research reports. Canaccord Genuity initiated coverage on shares of VBI Vaccines in a research report on Wednesday, November 1st. They set a “buy” rating and a $10.00 target price for the company. Zacks Investment Research raised shares of VBI Vaccines from a “hold” rating to a “buy” rating and set a $5.25 target price for the company in a research report on Saturday, December 23rd. BidaskClub downgraded shares of VBI Vaccines from a “hold” rating to a “sell” rating in a research report on Thursday, December 14th. Finally, BMO Capital Markets initiated coverage on shares of VBI Vaccines in a research report on Wednesday, November 15th. They set an “outperform” rating and a $11.00 target price for the company. Two research analysts have rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $8.75.
In other news, CEO Jeff Baxter acquired 10,000 shares of VBI Vaccines stock in a transaction on Tuesday, December 12th. The stock was acquired at an average cost of $3.89 per share, with a total value of $38,900.00. Following the transaction, the chief executive officer now owns 140,646 shares of the company’s stock, valued at approximately $547,112.94. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 34.10% of the company’s stock.
Hedge funds have recently modified their holdings of the business. Meitav Dash Investments Ltd. purchased a new position in VBI Vaccines in the fourth quarter valued at about $4,664,000. Millennium Management LLC boosted its stake in VBI Vaccines by 92.8% in the fourth quarter. Millennium Management LLC now owns 245,603 shares of the biopharmaceutical company’s stock valued at $1,049,000 after acquiring an additional 118,208 shares during the last quarter. TIAA CREF Investment Management LLC boosted its stake in VBI Vaccines by 24.8% in the fourth quarter. TIAA CREF Investment Management LLC now owns 78,369 shares of the biopharmaceutical company’s stock valued at $335,000 after acquiring an additional 15,557 shares during the last quarter. California State Teachers Retirement System boosted its stake in VBI Vaccines by 52.5% in the fourth quarter. California State Teachers Retirement System now owns 54,460 shares of the biopharmaceutical company’s stock valued at $233,000 after acquiring an additional 18,760 shares during the last quarter. Finally, Perceptive Advisors LLC boosted its stake in VBI Vaccines by 47.2% in the fourth quarter. Perceptive Advisors LLC now owns 9,665,843 shares of the biopharmaceutical company’s stock valued at $41,273,000 after acquiring an additional 3,100,000 shares during the last quarter. 31.28% of the stock is owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION NOTICE: This news story was published by Ticker Report and is the property of of Ticker Report. If you are viewing this news story on another website, it was illegally copied and republished in violation of U.S. & international copyright & trademark laws. The original version of this news story can be read at https://www.tickerreport.com/banking-finance/3228830/vbi-vaccines-inc-vbiv-expected-to-post-earnings-of-0-25-per-share.html.
About VBI Vaccines
VBI Vaccines Inc, formerly SciVac Therapeutics Inc, is a biotechnology company. The Company is engaged in developing various technologies that focus on vaccine protection. It has developed an enveloped virus like particle (eVLP) vaccine platform that allows for the design of enveloped VLP vaccines. It is involved in various projects related to human cytomegalovirus (CMV) and other antigens.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.